For 80% of colorectal cancers, Janus kinase (JAK) inhibitors may be effective
the ONA take:
According to a new study published in the journal Science Signaling, a team of researchers from around the world has demonstrated that more than 80% of colorectal cancers could be treated with Janus kinase (JAK) inhibitors. For the study, researchers tested JAK inhibitors in preclinical models of colorectal cancer and human colorectal cancer cells that have elevated levels of Wnt signaling.
A genetic mutation triggers increases levels Wnt pathway signaling, which in turn triggers more than 80% of colorectal cancers. According to the researchers, targeting the Wnt signaling pathway is difficult because normal cells in the intestine require low levels of Wnt signaling to maintain the healthiness of the gut.
The researchers sought to determine whether another signaling pathway, which involves JAK proteins, could be targeted to decrease tumor growth without harming the normal cells of the intestine. They found that inhibiting JAKs could halt cancer growth and no adverse effects were observed in the preclinical models; however, JAK inhibitors were only effective when the colorectal tumors were triggered by defective Wnt signaling, which is about 80-90% of colorectal cancers.
There are currently no JAK inhibitors approved by the U.S. Food and Drug Administration (FDA) for the treatment of cancer.
More than 80% of colorectal cancers could be treated with Janus kinase inhibitors
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Adding Pertuzumab to Adjuvant Therapy Is Beneficial for Some Women with Early Breast Cancer
- Clinical Trials May Benefit Oncology Patients
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Lenvatinib Improves OS, PFS in Radioiodine-Refractory Differentiated Thyroid Cancer in All Older Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|